Methods: To catalyse political commitment and to encourage domestic- and international-financing, we used published modelling data and key stakeholder interviews to develop an investment framework to demonstrate the return on investment for viral hepatitis elimination.
Results: The framework utilizes a public health approach to identify evidence- based national activities that reduce viral hepatitis-related morbidity and mortality, as well as international activities and critical enablers that allow countries to achieve maximum impact on health outcomes from investment to achieve WHO 2030 elimination targets.
Conclusion: Focusing on hepatitis B, this health policy paper employs the investment framework to estimate the substantial economic benefits of investing in the elimination of hepatitis B and demonstrates how such investments could be cost-saving by 2030.
Lay summary: Hepatitis B infection is a major cause of death from liver disease and liver cancer globally. To reduce deaths from hepatitis B infection, we need more people to be tested and treated for hepatitis B. In this paper, we outline a Framework of activities to reduce hepatitis B related deaths and ways in which Governments could pay for them.
|Number of pages||40|
|Journal||Journal of Hepatology|
|Publication status||Accepted/In press - 25 Aug 2020|
- viral hepatitis, hepatitis B, disease elimination, health financing, universal health coverage, cost-effectiveness